AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05811026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)
Description: * Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~* Visit 2 (W4): Clear + Brilliant™ Permea device periorbital treatment~* Visit 3 (W8): Clear + Brilliant™ Permea device periorbital treatment~* Visit 4 (W12): Four weeks after the third treatment, a follow-up assessment will be performed
Study NCT05703685 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 18F-PF-06445974
Description: Injected IV followed by PET scanning
Study NCT06348810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: The dual-task training is a combination of cognitive tasks and motor tasks which is done simultaneously or at the same time.
Study NCT06348810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Participants only receive cognitive tasks
Study NCT06348810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor training
Description: Participants only receive motor tasks
Study NCT06348810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: assist participants with activities of daily living, medication management, and social activities (such as singing, watching television).
Study NCT05271357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral TMS
Description: Stimulation begins with continuous TBS to the right dorsolateral prefrontal cortex (DLPFC) (120 seconds of uninterrupted bursts; 600 pulses per session) followed by intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds per hemisphere.
Study NCT05271357 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral TMS
Description: Stimulation involves only intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds.
Study NCT06518967 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: analytical performance study
Description: analytical performance study on left-over samples with the SiMoT IVD system for in vitro diagnostic tests
Study NCT06278558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interviews with a psychologist/psychiatrist
Description: All patients with a high score (≥11) on the HADS anxiety and/or depressive symptoms scale and who are not already receiving known psychological treatment or treatment mentioned in the file will be contacted by telephone by the investigator or a qualified person designated by him/her in order to conduct a telephone interview with the patient and refer him/her to a psychologist or psychiatrist if necessary. The number and percentage of consultations with a psychologist or psychiatrist following this telephone interview will be calculated in order to highlight the benefits of such a practice (HADS assessment + telephone interview with +/- referral) for earlier and easier referral. Depending on the number of patients contacted, consideration may be given to testing the effect of this approach on post-traumatic development.
Study NCT01363713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-114 ophthalmic solution
Study NCT04740099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOONER Video & Kit
Description: A brief animated video including basic instructions for opioid overdose response accompanied by a Naloxone kit with an info graphic.
Study NCT04740099 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: A handout including a map and list of locations offering this service.
Study NCT05682586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells
Description: Participants will receive two doses of UC-MSCs treatment, each dose will contain 1\*10\^6 cells/kg suspended in 100 ml albumin solution.
Study NCT05682586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paxlovid
Description: Participants will receive standard dose of paxlovid therapy, which contains 300mg namatevir and 100mg litonavir twice a day for a total course of 5 days.
Study NCT06175000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry.
Study NCT06175000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessment
Description: Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry.
Study NCT06175000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT06175000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry.
Study NCT06175000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Assessment
Description: Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry.
Study NCT06242782 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VRA + d-PTFE membrane
Description: VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced d-PTFE membrane
Study NCT06242782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VRA + e-PTFE membrane
Description: VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced e-PTFE membrane
Study NCT06242782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VRA + customised Ti-mesh
Description: VRA using a 50/50 particulate bone mix (xenograft+ autograft) + 3D printed Titanium mesh
Study NCT06242782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VRA + RPM
Description: VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Reinforced PTFE mesh
Study NCT05721924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerve group (PENG) block
Description: In PENG group, the patient will be given PENG block 30mls of 0.2% ropivacaine
Study NCT05521217 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MyotonPRO
Description: Evaluation of biomechanics and viscoelastic properties of posture muscle in children with Spinal Muscular Atrophy.~The biomechanical and viscoelastic properties of the posture muscle in children with Spinal Muscular Atrophy. will be measured with the MyotonPRO device.
Study NCT05721924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra-inguinal fascia iliaca compartment (S-FICB) block
Description: Patients in group B (S-FICB group) will be supra-inguinal fascia iliaca compartment block 30mls of 0.2% ropivacaine
Study NCT04854564 — intervention group
Intervention type: BEHAVIORAL
Intervention: Prehabilitation intervention
Description: The investigators will identify participants' perceived important information to develop a prehabilitation intervention in this study. Prehabilitation intervention consisting of physical activities, nutrition, and stress management.
Study NCT04854564 — intervention group
Intervention type: BEHAVIORAL
Intervention: Caregiver intervention
Description: The investigators will provide caregivers with variety of educational resources for patients experiencing ESLD.
Study NCT05982821 — intervention group
Intervention type: OTHER
Intervention: Artificial Intelligent
Description: Artificial intelligence assisted radiologists to extract ultrasound features of thyroid nodules.
Study NCT04771793 — intervention group
Intervention type: BEHAVIORAL
Intervention: new physical restraint protocols
Description: new physical restraint protocols
Study NCT05178225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ubiquinol (reduced coenzyme Q10)
Description: supplementation with ubiquinol (reduced coenzyme Q10), in a daily dose of 2x100 mg. one morning after breakfast, and second dose after dinner.
Study NCT05178225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mountain spa rehabilitation
Description: special spa rehabilitation in the mountain High Tatras; Functional capacity of the lungs (6MWT) at before and after 16-18 days of rehabilitation, Borg scale for dyspnea and oxygen saturation SpO2 (%) were monitored.
Study NCT05178225 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 2x14 ml of peripheral blood collected in a tube with anticoagulant
Description: 2x14 ml of peripheral blood collected in a tube with anticoagulant
Study NCT05178225 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 2x14 ml of peripheral blood collected in a tube with anticoagulant
Description: 2x14 ml of peripheral blood collected in a tube with anticoagulant
Study NCT05419245 — intervention group
Intervention type: OTHER
Intervention: Guided Health History for Freeman-Burian Syndrome Questionnaire
Description: Completed during the interview. The Guided Health History for Freeman-Burian Syndrome Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
Study NCT05419245 — intervention group
Intervention type: OTHER
Intervention: Freeman-Burian syndrome Semi-Structured Quality of Life Interview
Description: Completed during the interview. Freeman-Burian syndrome Semi-Structured Quality of Life Interview is a quality of life interview for Freeman-Burian syndrome, taking into consideration individual's total health.
Study NCT05311293 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopy
Description: Observe the extent of colonic lesions and obtain intestinal mucosal samples
Study NCT05419245 — intervention group
Intervention type: OTHER
Intervention: Medical Records Review
Description: Review of medical records will be used, along with Guided Health History for Freeman-Burian Syndrome Questionnaire to assess patient histories and outcomes.
Study NCT05419245 — intervention group
Intervention type: OTHER
Intervention: PTSD Checklist for DSM-5
Description: Completed by patients before the interview. The PTSD Checklist for DSM-5 is a 20-item questionnaire. Each item is rated 0-4, with 0 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms.
Study NCT05419245 — intervention group
Intervention type: OTHER
Intervention: Modified Flanagan Quality of Life Scale
Description: Completed by patients before the interview. The Modified Flanagan Quality of Life Scale is a 16-item survey designed for use in persons with chronic illness. Each item is rated 1-7, with 1 being Terrible and 7 being Delighted. Higher scores suggest the person may be experiencing a better quality of life.
Study NCT05419245 — intervention group
Intervention type: OTHER
Intervention: Center for Epidemiologic Studies Depression Scale
Description: Completed by patients before the interview. The Center for Epidemiologic Studies Depression Scale is a 20-item survey that asks about depressive feelings and behaviours in the past week. Each item is rated 0-3, with 0 being Rarely or none of the time (less than 1 day) and 3 being Most or all of the time (5-7 days). Lower scores suggest the person may be experiencing fewer symptoms.
Study NCT05419245 — intervention group
Intervention type: OTHER
Intervention: Review of Systems
Description: Completed during the interview. A review of systems is a checklist of medical problems.
Study NCT05419245 — intervention group
Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Appearance of the Face
Description: Completed by patients. The FACE-Q \| Craniofacial - Appearance of the Face is a 9-item questionnaire. Each item is rated 1-4, with 1 being Not at All and 4 being Very Much. Lower scores suggest the person may be less pleased with the appearance of their face.
Study NCT06399679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
Study NCT06399679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
Study NCT05936333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: up to 25 mL of blood collection for the adults and saliva collection for the minor at inclusion, and placenta collection at childbirth
Study NCT05936333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biological collection
Description: up to 25 mL of blood collection for the adults and saliva collection for the minor at inclusion, and placenta collection at childbirth
Study NCT05936333 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biological collection
Description: up to 25 mL of blood collection for the adults and saliva collection for the minor at inclusion, and placenta collection at childbirth
Study NCT06216730 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic papillectomy
Description: patients undergoing endoscopic papillectomy will be included and treated according to the study algorithm.~* A papillary adenoma (abnormal tissue growth/ tumour at junction of bile duct \& intestines) will be removed completely by cutting \& removing abnormal tissue growth using a flexible tube containing a camera through the mouth.~* After the procedure you will be admitted in the hospital for at least 24 hours for observation,~* You will be asked to use medications which decrease acid production (PPIs- proton pump inhibitors) in stomach for 2 weeks to decrease the risk of bleeding.
Study NCT05519813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Use Metformin for 3 months to treat PCOS
Study NCT05519813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets
Description: Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS
Study NCT06513117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change
Description: healthy conversations to support behaviour change
Study NCT06513117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary support
Description: Guidance on healthy eating
Study NCT06513117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing pattern retraining
Description: guidance on breathing pattern in exercise
Study NCT06513117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise intervention prescribed to participant fitness level
Study NCT05896319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Description: Post-operative application of Hyaluronic acid gel 3 times per day (8 hours distance between each application) for 7 days after oral hygiene and without swallowing, eating or drinking for one hour after the application, as follows: wash your hands thoroughly before each application, apply a layer of gel on the injured mucosa, massage with a finger in order to facilitate spreading of the product over the treated area.
Study NCT05111483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tupler technique
Description: The subjects with DRA will receive Tupler's technique treatment plan for 18 weeks in which four steps will be followed.~1. Repositioning with diastasis rehab splint :~2. Protect the connective tissue~3. Tupler's technique exercises (elevators, contractions, standing pelvic tilt, head lifts, leg slides, low back stretch) with 10 repetitions for each exercise.~4. Diastasis safe exercises program to maintain the gains
Study NCT05111483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: The subjects with DRA will receive conventional physical therapy treatment for 16 weeks in which researcher will follow these steps:~1. Tie a scarf around abdomen while performing exercises~2. Exercise program for diastasis recti abdominal muscles; sit ups, reverse sit ups, reverse trunk twist and U-seat exercises. (10 repetitions for each exercise)~3. Respiratory rehabilitation manoeuvre
Study NCT05598580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules (25 mg) were administered orally on days 1-21 of a 28-day cycle for 24 weeks with continuous antiretroviral therapy.
Study NCT05598580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosylmethionine
Description: Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy.
Study NCT05624827 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing DNA methylation test for predicting prognosis of untreated CIN 2
Description: After being diagnosed with CIN 2, patients will first be contacted by telephone and invited to participate in the study. If patients agree to participate in the research, they will sign a consent to participate in the research. After that, we will perform a colposcopy and take a cervical swab for analysis with the QIAsure Methylation Test Kit (Qiagen, Gaithersburg, USA), which will determine the methylation of tumor suppressor genes FAM19A4 and has-mir-124. Patients will complete a questionnaire. The total duration of tracking in both groups will be two years. The QIAsure Methylation Test will be performed to analyze methylation. It is a methylation-specific PCR test that detects hypermethylation of the tumor promoter suppressor genes FAM19A4 and has-mir-124. The samples on which we will use this test are bisulfite-converted DNA obtained by triage test for high-risk HPV - Hybrid Capture 2 HPV DNA Test (hc2, Qiagen, Gaithersburg, USA).
Study NCT06219642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness using virtual reality
Description: In each session, participants will be led through the following mindfulness script while using the VR device here is an abbreviated version with excerpts:~Look around. Try to bring yourself to the moment you are in. Notice the presence of the scene around you. How does the air feel against your skin? How do your feet feel against the ground? Where are you? What do you see? Do you hear anything? What do you smell? What do you taste? While you stay seated, imagine you are walking. What body sensations are you experiencing? What thoughts are you having? What emotions are you feeling? At the end of the intervention, participants are asked questions like, What did you notice about your thoughts and mood before, during, and after the VR session? Did you notice a change in how your body felt or your emotions? Was there anything difficult or uncomfortable about the experience that you feel comfortable sharing?
Study NCT05344014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: In experimental groups, before topical anesthesia, PBMT was applied by utilizing a diode laser (EpiX; Biolase technology, inc., USA) with a continuous wavelength of 940 nm on a 400-μm fiber with only biostimulation properties. In accordance with the recommendations of the device's manufacturer, it was applied using circular motions in a manner as slowly as possible (an average of 33-36 circular movements in 60 s)
Study NCT05344014 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the control group (placebo), the laser probe was directed to the mucosa for (buccal and palatal area), but not activated, and the sound of the laser device previously recorded on the mobile telephone was played for the same time of experimental group in order to provide similar conditions
Study NCT06379711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation (tSCS)
Description: Transcutaneous spinal cord stimulation (tSCS) will be delivered via a non-invasive central nervous system stimulator TESCoN or SCONE (SpineX Inc., CA - experimental type II medical devices) through self-adhesive electrode(s) placed on the skin between spinous processes over the midline of the vertebral column as the cathode(s) and two rectangular electrodes placed symmetrically on the skin over the iliac crests as anodes. Stimulation will be applied at various waveforms and frequencies (ranging between 1Hz and 90Hz) with and without a carrier frequency. Current amplitude will start at 10mA and proceed incrementally until tolerable or responses plateau. If spasticity occurs or is uncomfortable, the current will be decreased. Specific areas for electrode placement will be examined and prepared to reduce skin impedance. tSCS will be delivered under the supervision of a physician (Dr. Krassioukov/Dr. Berger) by trained doctoral/post-doctoral trainees.
Study NCT02379299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiaCon dual-hormone closed-loop glucose control algorithm
Description: Dual-hormone closed-loop glucose control
Study NCT02379299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DiaCon single-hormone closed-loop glucose control algorithm
Description: Single-hormone closed-loop glucose control
Study NCT05000944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breakfast omission (BO)
Description: this group will not be provided with a breakfast until lunch time (at 12:30).
Study NCT05000944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early-morning breakfast consumption (EM-BC)
Description: this group will be provided with an early morning breakfast (at 08:30).
Study NCT05000944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mid-morning breakfast consumption (MM-BC)
Description: this group will be provided with a mid (late) morning breakfast (at 10:30).
Study NCT02205853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The patient-directed (PD) strategy
Description: The patient-directed strategy will be designed to embed the success of implementation of PCRPs by influencing the patients.